BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2020 / 07:50PM GMT
Release Date Price: €25 (-1.57%)
Carter Gould;Barclays;Senior Analyst

Good afternoon. I'm Carter Gould, senior biopharma analyst here at Barclays. I'm delighted to welcome BioXcel to the Barclays virtual Global Healthcare Conference. BioXcel has been one of those stories where the company just sort of kept their head down in the past 2 years, continue to execute, and it's good to see their lead asset, BXCL501, come into greater focus from investors over the past couple of months.

We're joined today by the company's CEO and Founder, Vimal Mehta. He will provide the presentation today. Vimal?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thank you, Carter. Good afternoon. And thank you for joining us today. As a reminder, I will be making forward-looking statements regarding our clinical programs and business outlook in addition to regulatory product development. That's on Slide #2.

Coming back to Slide #3. For those who are following the slide, it's a virtual presentation, so I will do my best to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot